Pentixapharm : Financial document (Pentixapharm Q1 2026 e)

About this update from Pentixapharm Holding Ag

Q1 REPORT 2 0 2 6 . PENTIXAPHARM ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌CONTENT 03 AT A GLANCE ON THE FIRST THREE MONTHS 2026 04 A. INTERIM GROUP MANAGEMENT REPORT 04 A.1 EARNINGS PERFORMANCE 04 A.2 NET ASSETS AND FINANCIAL POSITION 05 A.3 OUTLOOK 05 A.4 RISKS AND OPPORTUNITIES 05 A.5 ADDITIONAL DISCLOSURES 06 B. INTERIM CONSOLIDATED FINANCIAL STATEMENTS 06 B.1 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 07 B.2 CONSOLIDATED BALANCE SHEET 08 B.3 CONSOLIDATED STATEMENT OF CASH FLOWS 09 B.4 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 10 B.5 NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS 13 C. ADDITIONAL INFORMATION 13 C.1 STATEMENT BY LEGAL REPRESENTATIVES (DECLARATION OF ACCURACY) A B C 13 IMPRINT 2 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌AT A GLANCE ON THE FIRST THREE MONTHS 2026 the first quarter of 2026 was a quarter of regulatory and clinical progress for pentixapharm across two complementary value drivers: diagnostics and thera-nostics. Regulatory confirmation of the diagnostic panda Phase 3 lead program In January , in the formal Type B Pre-ind meeting, the fda confirmed the conceptual approach of the planned Phase 3 panda study with [⁶⁸Ga]Ga-PentixaFor in treatment-resistant hypertension and primary aldosteronism - a key milestone for our planned Phase 3 lead program in primary aldosteronism (pa), with a clear regulatory line of sight on the path to an ind submission. Clinical evidence reinforces differentiation and feasibility This progress was complemented in February by newly published real-world data from European reference centers, which demonstrate the clinical utility of [⁶⁸Ga]PentixaFor pet/ct in primary aldosteronism using harmonized diagnostic criteria, further reinforc- ing the transferability into clinical practice and the robustness of the Phase 3 approach. Regulatory start of the oncology conditioning program (penthera) At the end of February , we received from the u.s. Food and Drug Administration the "Study May Proceed" notice for the clinical evaluation of the theranostic pair PentixaTher/PentixaFor within the hemato-on-cology Phase 1 program penthera - a key step toward initiating our therapeutic oncology program in conditioning prior to stem cell transplantation and toward establishing a stand-alone value-creation pathway within the cxcr4 platform. Financial discipline strengthens execution capability With the publication of the 2025 Annual Report in March , we closed the quarter and were able to demonstrate the effectiveness of our consistent cost control and the impact of the implemented efficiency measures, with the annual loss reduced by €2.5 million ver- sus the most recent forecast. This also lays the financial foundation for the next stage of clinical evaluation of our cxcr4 platform. Operational reinforcement for Phase 3 and commercialization At the end of the quarter , with the appointment of Erik Merten as Chief Technology Officer to the Management Board, we further strengthened the operational foundation for Phase 3 and commercialization. Going forward, Erik Merten will be responsible for technology development and supply logistics at Management Board level and brings proven expertise from the successful development of commercial radiopharmaceuticals at Bayer. 3 PENTIIXAPHARM ZQWUIASRCTHEERNLBYERREIPCOHRTTQ1 20265 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌INTERIM GROUP MANAGEMENT REPORT The condensed interim consolidated financial statements and the interim group management report have not been subjected to an audit review by an independent auditor. ‌EARNINGS PERFORMANCE In the first quarter of 2026, the Pentixapharm Group recorded a loss of €3.2 million (-€0.13 per share), compared with a loss of €4.0 million (-€0.16 per share) in the same period of the previous year. No revenue was realized in the reporting period (previous year: €19 thousand). Other operating income totaled €59 thousand. In the first quarter of 2025, other operating income amounted to €169 thousand. In the previous year, this mainly consisted of project grants, which did not recur in the first quarter of 2026. The cost of materials and external services for research and development amounted to €513 thousand in the first quarter of 2026 (previous year: €1,215 thousand); personnel expenses came to €1,174 thousand (previous year: €1,326 thousand). Other operating expenses of €490 thousand (previous year: €842 thousand) mainly comprise consulting costs, costs for investor relations, rental and leasing costs, and it costs. Of the €916 thousand in depreciation and amortization of fixed assets (previous year: €942 thousand), 911 thousand (previous year: €913 thousand) relates to scheduled amortization of intangible assets. The financial result includes expenses from the measurement of financial instruments of €122 thousand (previous year: €76 thousand), interest expenses of €31 thousand (previous year: €0 thousand), and interest income of €6 thousand (previous year: €101 thousand). The income from taxes on income of €98 thousand in the first quarter of the previous year related exclusively to deferred taxes in connection with the amortization of intangible assets. ‌NET ASSETS AND FINANCIAL POSITION BALANCE SHEET The total assets as of March 31, 2026 changed only marginally compared with the 2025 annual financial statements, decreasing by €0.7 million to €41.2 million (previous year: €41.9 million). On the assets side, non-current assets decreased by €1.0 million to €34.8 million. This was mainly the result of €0.9 million in scheduled depreciation and amortization of fixed assets and a €0.1 million reduction in deferred tax assets. Current assets increased in total by €0.3 million, from €6.0 million to €6.3 million. Cash and cash equivalents rose by €0.5 million to €5.2 million, while other current assets decreased by €0.2 million to €1.2 million. Changes on the liabilities and equity side mainly relate to equity and non-current liabilities. Equity decreased by €2.9 million to €32.1 million as of March 31, 2026. The decrease was mainly the result of the loss for the period of €-3.2 million (previous year: €-4.0 million). This was partly offset by the equity component of the tranches of the convertible bond drawn down at the beginning of February 2026, in the amount of €0.2 million, as well as by an addition to capital reserves in connection with share-based compensation in the amount of €0.1 million. The equity ratio stands at 78% (previous year: 84%). Non-current liabilities increased in total by €2.7 million to €6.1 million. The increase comes from €2.8 million in the debt component of the six tranches of the convertible bond drawn down, partly offset by a €0.1 million reduction in deferred tax liabilities. LIQUIDITY Operating cash flow amounted to €-2.5 million in the first quarter of 2026 (previous year: €-5.2 million). In addition to the loss for the period of €3.2 million (previous year: €4.0 million), the decrease in trade payables and other liabilities of €0.5 million had the most significant negative effect on operating cash flow. This was offset by depreciation, amortization and other non-cash expenses of €1.2 million, as well as the decrease in trade receivables and other assets of €0.1 million. ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 No new investments in intangible assets and property, plant and equipment were made in the first quarter of 2026, while in the same period of the previous year €0.6 million in cash was used for investments. Cash inflow from financing activities amounted to €3.0 million in the first quarter of 2026 (previous year: €0 million). The cash inflow resulted from the call-up at the beginning of February 2026 of six tranches of €500,000 each from a convertible bond subscribed by Eckert & Ziegler se. There were no inflows or outflows from financing activities in the first quarter of the previous year. In total, cash and cash equivalents increased by €0.5 million as of March 31, 2026 compared with year-end 2025, to €5.2 million. ‌OUTLOOK The forecast for the 2026 financial year published on March 26, 2026 remains unchanged. The Management Board continues to anticipate a loss of approximately €21.6 million. ‌RISKS AND OPPORTUNITIES In the Annual Report 2025, we described risks that may have significant adverse effects on our business situation, assets, financial position, results of operations and reputation. The most significant opportunities and the design of our risk-management system were also presented. Additional risks and opportunities of which we are not aware, or that we currently consider to be immaterial, could also affect our business activities. With the exception of the uncertainties relating to the liquidity criteria, no further risks have been identified at present that, whether individually or in combination with other risks, could jeopardize our continued existence. ‌ADDITIONAL DISCLOSURES EMPLOYEES As of March 31, 2026, the Pentixapharm Group employed 36 people. Compared with the average for the 2025 financial year (61 employees), the headcount has thus decreased significantly. The reduction in headcount took place as planned, in the context of the strategic refocusing and the related prioritization of development programs. PENTIIXAPHARM ZQWUIASRCTHEERNLBYERREIPCOHRTTQ1 20265 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌INTERIM CONSOLIDATED FINANCIAL STATEMENTS ‌B.1 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME € thousand Jan 1 to Mar 31, 2025 Jan 1 to Mar 31, 2026 Revenue 19 0 Proceeds from the sale of rights/patents 0 0 Other operating income 169 59 Cost of materials and external services for research and development -1,215 -513 Personnel expenses -1,326 -1,174 Other operating expenses -842 -490 Earnings before interest, taxes, depreciation and amortization (ebitda) -3,195 -2,118 Depreciation of fixed assets -942 -916 Earnings before interest and taxes (ebit) -4,137 -3,034 Financial result 25 -148 Earnings before taxes (ebt) -4,112 -3,182 Income taxes 98 0 Profit or loss attributable to shareholders of the parent company/Consolidated net income -4,013 -3,182 Other comprehensive income 0 2 Consolidated comprehensive income -4,013 -3,180 Earnings per share Diluted*/Undiluted (€ per share) -0.16 -0,13 Weighted average number of shares in circulation (diluted*/undiluted) - in thousand units) 24,783 24.783 * Due to the net loss incurred in the reporting period, potential ordinary shares (rsus) were not included in the calculation of diluted earnings per share, as their inclusion would have had a reducing effect on the loss per share (antidilutive effect). The company has a facility for the issuance of convertible bonds with an aggregate principal amount of up to €18.5 million. As of the reporting date, six tranches of €0.5 million each had been called from this facility. In the event of a future full drawdown and conversion at the agreed conversion price of €4.70 up to 3,936,170 new ordinary shares could be issued. In accordance with ias 33.70 (c) , these potential ordinary shares were not included in the calculation of diluted earnings per share. ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌B.2 CONSOLIDATED BALANCE SHEET Assets € thousand Dec 31, 2025 Mar 31, 2026 Non-current assets Other intangible assets 32,282 31,371 Property, plant and equipment 36 20 Deferred tax assets 3,328 3,230 Financial assets 227 216 Total non-current assets 35,873 34,837 Current assets Cash and cash equivalents 4,624 5,163 Trade receivables 31 16 Income tax receivables 189 190 Other current assets 1,142 962 Total current assets 5,986 6,331 Total assets 41,859 41,168 Liabilities and Equity € thousand Dec 31, 2025 Mar 31, 2026 Equity Subscribed capital 24,795 24,795 Capital reserves 38,727 38,989 Net profit/loss -28,438 -31,620 Treasury shares -12 -12 Equity attributable to shareholders of the parent company 35,072 32,152 Total equity 35,072 32,152 Non-current liabilities Deferred tax liabilities 3,328 3,230 Other non-current liabilities 0 2,842 Total non-current liabilities 3,328 6,072 Current liabilities Trade payables 2,435 1,857 Other current liabilities 1,024 1,087 Total current liabilities 3,459 2,944 Total assets 41,859 41,168 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌B.3 CONSOLIDATED STATEMENT OF CASH FLOWS € thousand Jan 1 to Mar 31, 2025 Jan 1 to Mar 31, 2026 Cash flow from operating activities Profit (+)/Loss (-) -4,013 -3,182 Adjustments for: Depreciation, amortization and impairments 942 916 Loss on disposal of fixed assets 0 11 Change in deferred taxes -98 0 Income tax payments -26 -1 Other non-cash expenses (+)/income (-) 76 240 Change in trade receivables and other assets not attributable to investing activities 5,632 83 Change in trade payables and other liabilities not assignable to investing activities -7,750 -534 Cash outflow from operating activities -5,237 -2,467 Cash flow from investing activities: Payments for investments in intangible assets and property, plant and equipment -605 0 Cash inflow from investing activities -605 0 Cash flow from financing activities: Proceeds from the issuance of convertible bonds 0 3,000 Cash inflow from financing activities 0 3,000 Exchange-rate-related changes in cash and cash equivalents 0 0 Change in cash and cash equivalents -5,842 539 Cash and cash equivalents at the beginning of the period 23,232 4,624 Cash and cash equivalents at the end of the period 17,390 5,163 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌B.4 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Equity attributable to share- holders of Amounts in € thousand, Number of Subscribed Capital Net profit/ Treasury the parent excluding number of shares shares capital reserves loss shares company As of December 31, 2024 24,795,477 24,795 37,475 -12,843 -12 49,415 Error correction ias 8 0 0 0 916 0 916 As of January 1, 2025 24,795,477 24,795 37,475 -11,927 -12 50,331 Consolidated comprehensive income 0 0 0 -16,511 0 90 Share-based compensation 0 0 1,252 0 0 -3,182 Costs of the capital increase 0 0 0 0 0 0 As of December 31, 2025 24,795,477 24,795 38,727 -28,438 -12 35,072 Equity attributable to share- holders of Amounts in € thousand, Number of Subscribed Capital Net profit/ Treasury the parent excluding number of shares shares capital reserves loss shares company As of January 1, 2026 24,795,477 24,795 38,727 -28,438 -12 35,072 Consolidated comprehensive income 0 0 2 -3,182 0 -3,180 Issuance of convertible bonds 0 0 170 0 0 170 Share-based compensation 0 0 90 0 0 90 As of March 31, 2026 24,795,477 24,795 38,989 -31,620 -12 32,152 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌B.5 NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS GENERAL INFORMATION These interim consolidated financial statements as of March 31, 2026 comprise the financial statements of Pentixapharm Holding ag and its subsidiaries. The condensed interim consolidated financial statements and the interim group management report have not been subjected to an audit review by an independent auditor. DISCLOSURES ON ACCOUNTING POLICIES The condensed interim consolidated financial statements of Pentixapharm Holding ag (ptx) as of March 31, 2026 were prepared in accordance with the International Financial Reporting Standards (ifrs) applicable to interim financial reporting. All standards of the International Accounting Standards Board (iasb), London, applicable in the eu as of the reporting date, as well as the relevant interpretations of the ifrs Interpretations Committee (ifric) and the Standing Interpretations Committee (sic), have been taken into account. The interim financial statements do not comprise all of the disclosures usually found in financial statements for a full financial year and are thus condensed. Accordingly, these interim financial statements should be read in conjunction with the consolidated financial statements of Pentixapharm Holding ag as of December 31, 2025. The accounting policies explained in the notes to the 2025 consolidated financial statements have been applied unchanged, except with respect to the initial application of amended standards, which, however, had no effect. When preparing the consolidated financial statements in accordance with ifrs, it is necessary to make estimates and assumptions that affect the amount and presentation of the assets, liabilities, income and expenses recognized. Material assumptions and estimates are made with respect to useful life, recoverable amount of fixed assets, and the recognition and measurement of provisions. Due to rounding, individual figures may not add up exactly to the totals shown. This interim report contains all the necessary information and adjustments required to provide a true and fair view of ptx's net assets, financial position and results of operations for the interim report. The interim results of the current financial year do not necessarily permit conclusions as to the development of future results. SCOPE OF CONSOLIDATION The consolidated financial statements of Pentixapharm Holding ag include all companies in respect of which Pentixapharm Holding ag has, directly or indirectly, the ability to determine financial and business policy (control concept). CHANGES IN THE SCOPE OF CONSOLIDATION There were no changes to the scope of consolidation compared with December 31, 2025. COMPANY ACQUISITIONS AND DISPOSALS No companies were acquired or disposed of during the first quarter of 2026. HOLDINGS OF TREASURY SHARES As of March 31, 2026, the Pentixapharm Group held 12,429 treasury shares. Arithmetically, this represented 0.05% of the company's share capital. CURRENCY TRANSLATION The following exchange rates were used for currency translation: Closing rate Closing rate Average rate Average Country Currency Mar 31, 2026 Mar 31, 2025 Q1/2026 rate Q1/2025 usa usd 1.14980 n.a. 1.17068 n.a. MATERIAL TRANSACTIONS WITH RELATED PARTIES In accordance with ias 24, transactions must be disclosed if they involve persons or companies that control, or are controlled by, Pentixapharm Holding ag. Details of transactions between the company and other related parties are disclosed below. Transactions of Pentixapharm Holding ag with related parties are conducted under the arm's-length principle. PENTIXAPHARM QUARTERLY REPORT 1 2026 In addition to the Management Board and the members of the Supervisory Board, the following are considered to be other material related parties for the current financial year: Eckert & Ziegler se and all of its direct and indirect subsidiaries. Eckert Wagniskapital und Frühphasenfinanzierung GmbH, which holds 31.2% of the shares of Eckert & Ziegler se and 36.0% of the shares of Pentixapharm Holding ag, and whose principal shareholder, Dr. Andreas Eckert, is Chairman of the Supervisory Board of Eckert & Ziegler se and of Pentixapharm Holding ag. ptx considers Dr. Eckert a related party and "ultimate controlling party", as in the past he indirectly held a quorum-majority presence at the Annual General Meetings of Eckert & Ziegler se and Pentixapharm Holding ag. The articles of association of Pentixapharm Holding ag grant Eckert Wagniskapital- und Frühphasenfinanzierung GmbH the right to nominate one third of the Supervisory Board for as long as it holds at least 3% of the shares of ptx. Glycotope GmbH, in which Dr. Andreas Eckert holds 8.76% of the shares indirectly through elsa 1 Beteiligungen GmbH, and in which Henner Kollenberg (Member of the Management Board of Pentixapharm Holding ag) served as Managing Director until March 1, 2026. The following material transactions with related parties were carried out in the first quarter of 2026: Eckert & Ziegler Radiopharma GmbH provided various services in the context of the development projects of Pentixapharm ag. The expenses incurred by Pentixapharm ag for these services in the first quarter of 2026 amounted to €93 thousand (previous year: €96 thousand ). In the previous year, Pentixapharm ag provided services for Eckert & Ziegler Eurotope GmbH under a research project, generating revenue of €17 thousand in the first quarter of 2025. In the first quarter of 2026, Eckert & Ziegler Eurotope GmbH supplied goods worth €5 thousand to Pentixapharm ag. Under an existing business management agreement with Glycotope GmbH, Pentixapharm received a fee of €20 thousand (previous year: €3 thousand). In February 2025, Pentixapharm ag paid €6,091 thousand to Glycotope GmbH to settle an existing existing earn-out liability. Pentixapharm Holding ag, as issuer, and Eckert & Ziegler se, as subscriber, concluded the subscription agreement for a convertible bond on August 30, 2024. The (37) bonds will only be delivered to Eckert & Ziegler se once Pentixapharm Holding ag has called the payment amounts due from Eckert & Ziegler se and payment has been made. Up to March 31, 2026, six tranches of €500,000 each had been called by ptx. The liability of ptx to Eckert & Ziegler se arising from the bonds amounts to €3.0 million as of March 31, 2026, plus accrued interest of €19 thousand For the remaining 31 bonds, a pending transaction exists; consequently, the bonds themselves are not recognized. Based on the subscription agreement, however, rights and obligations of the parties already arise, which are reflected in accounting terms as a derivative. This resulted in an asset of €290 thousand at the end of the quarter (December 31, 2025: €388 thousand). For the terms and conditions of the convertible bond, we refer to the explanations under Note 24 of our 2025 Annual Report. The balances of ptx with related parties in respect of receivables and payables as of March 31, 2026 and December 31, 2025 are as follows: € thousand Dec 31, 2025 Mar 31, 2026 Receivables from related parties 19 15 Liabilities to related parties 40 3,089 CHANGES IN THE MANAGEMENT BOARD Effective March 30, 2026, Dr. Erik Merten was newly appointed as Chief Technology Officer (cto) to the Management Board of Pentixapharm Holding ag. DISCLOSURES CONCERNING FINANCIAL INSTRUMENTS Financial assets measured at fair value include, as of March 31, 2026, the exercise rights in connection with the above-mentioned convertible bond. The fair value of this derivative financial instrument as of March 31, 2026 was €290 thousand (December 31, 2025: €388 thousand). Financial liabilities measured at fair value include the following amounts as of March 31, 2026: Liabilities of €217 thousand (December 31, 2025: €227 thousand) from share-based compensation to employees, which are to be settled with shares of Eckert & Ziegler se. PENTIXAPHARM QUARTERLY REPORT 1 2026 In the area of financial liabilities, a convertible bond with a nominal volume of €3.0 million existed as of March 31, 2026. The split into an equity component and a debt component was carried out in accordance with ias 32. The carrying amount of the debt component, measured at amortized cost, developed as follows in the first quarter of 2026: Carrying amount at the call date: €2,830 thousand Interest expense (recognized in profit or loss): €31 thousand of which cash interest (4% nominal): €19 thousand of which accretion (effective-interest method): €12 thousand Interest paid: €-0 thousand Carrying amount as of March 31, 2026: €2,861 thousand Net income from financial instruments under ifrs 7.20 in the first quarter of 2026 was composed as follows: The net result from financial instruments measured at fair value through profit or loss (fvtpl) amounted to €-122 thousand (previous year: €-76 thousand). This resulted from the measurement of shares of €-25 thousand (previous year: €0 thousand) and from the market valuation of call rights from the convertible bond of €-97 thousand (previous year: €-76 thousand). No gains or losses on the disposal of financial instruments arose in the reporting period or in the first quarter of the previous year. Other operating income includes foreign-currency gains from financial instruments of €11 thousand (previous year: €23 thousand), and other operating expenses include foreign-currency losses from financial instruments of €6 thousand (previous year: €2 thousand). The interest result comprises interest income of €6 thousand (previous year: €101 thousand) and interest expenses for financial liabilities of €31 thousand (previous year: €0 thousand). The fair value of cash and cash equivalents, of trade receivables and payables, and of other current liabilities and other receivables is approximately equal to the carrying amount. The primary reason for this is the short maturity of such instruments. Going concern - Continuation of business activities - As of March 31, 2026, the Pentixapharm Group has cash reserves of €5.2 million (Dec 31, 2025: €4.6 million). On February 2, 2026, the Group called 6 tranches of €500,000 each - i.e., €3.0 million in total - from a convertible bond subscribed by Eckert & Ziegler se. In addition, the Group has the option, if necessary, to call up to a further 31 tranches of €500,000 each, i.e., a further €15.5 million in total, from this convertible bond. The business model is characterized by high research and development expenses and administrative costs, which the company is currently unable to finance from cash flow from operating activities. As the company is in a clinical development stage, it expects that, for the foreseeable future as well, it will need to raise additional funds through public or private equity or debt financing, including grants from public institutions, corporate collaborations, or licensing agreements. The company is focusing its resources on advancing the clinical development of its lead product candidates in prioritized indications. Other development projects have been deferred until additional funds are available. In the event of receiving additional funds, the company plans to expand its development portfolio step by step. The current liquidity planning shows that, at the time these interim financial statements are prepared, the Group is equipped with sufficient financial means to meet its current obligations and liabilities at least until the end of the first quarter of 2027. To secure liquidity beyond this period, the Management Board plans to raise additional capital. We see significant potential in monetizing our IP through outlicensing. In addition, we are evaluating the possibility of a capital increase to strengthen the equity base. At the time these interim financial statements are prepared, the Management Board considers it predominantly probable that these measures can be successfully implemented. Nevertheless, the current situation indicates that a material uncertainty exists which may cast significant doubt on the Group's ability to continue as a going concern. The financial statements are prepared on the going-concern basis. EVENTS AFTER THE REPORTING DATE There were no events after the reporting date that had a material impact on the net assets, financial position or results of operations of Pentixapharm Holding ag. PENTIIXAPHARM ZQWUIASRCTHEERNLBYERREIPCOHRTTQ1 20265 ‌PENTIXAPHARM QUARTERLY REPORT 1 2026 ‌ADDITIONAL INFORMATION ‌STATEMENT BY LEGAL REPRESENTATIVES (DECLARATION OF ACCURACY) To the best of our knowledge, we affirm that, in accordance with the applicable accounting principles for interim financial reporting, the Interim Group Financial Statements provide a true and fair view of the Group's assets, financial position and results of operations, and that the Interim Group Management Report accurately reflects the business performance, including the results of operations and the situation of the Group, in such a manner as to provide a true and fair view, and describes the material opportunities and risks of the expected development of the Group during the remainder of the financial year. Berlin, May 7, 2026 Dr. Dirk Pleimes Chairman of the Management Board Henner Kollenberg Member of the Management Board Dr. Erik Merten Member of the Management Board ‌IMPRINT Pentixapharm Holding ag Robert-Rössle-Straße 10 13125 Berlin, Germany Contact +49 30 94 89 32 20 [email protected] https://www.pentixapharm.com IR Contact Investor Relations +49 30 94 89 32 32 [email protected] Design 2dKontor, Aabenraa, Denmark

View stock analysis, news, and events for Pentixapharm Holding Ag